Deep Data Dive: Highlights From ASCO 2024 on the Treatment of High-Risk BCG-Unresponsive NMIBC

After briefly introducing themselves, Trinity Bivalacqua, MD, PhD and Mark Tyson, MD, MPH discuss approximately how many newly diagnosed bladder cancer patients have non-muscle invasive bladder cancer, or NMIBC.

Trinity Bivalacqua, MD, PhD and Mark Tyson, MD, MPH discuss the current shortage of BCG therapy and how that has impacted clinical practice management.

Experts discuss the rate of recurrence following first-line BCG therapy.

Experts discuss available therapies beyond BCG.

Experts give an overview of the ASCO 2024 data.

Experts discuss the patient quantity and qualifications for the CORE-001 trial.

Experts compare Cretostimogene and BCG Administration Methods

Experts discuss the results of the CORE-001 Trial.

Key opinion leaders examine the comparative safety profiles and response durations of combination therapy versus monotherapy in the treatment of BCG-unresponsive carcinoma in situ with or without papillary disease.

Panelists discuss how the combination therapy of cretostimogene plus pembrolizumab offers a promising new approach for managing BCG-unresponsive non-muscle-invasive bladder cancer, highlighting its potential benefits and the implications of its FDA Breakthrough Therapy Designation for clinical practice.

Panelists discuss whether the trial results support investigating cretostimogene with other checkpoint inhibitors and provide insights into notable ongoing trials exploring cretostimogene for intermediate- or high-risk NMIBC, such as BOND-003 and PIVOT-006.

Panelists discuss their views on using cretostimogene as monotherapy versus combination therapy, the importance for urologists to stay updated on advances for managing BCG-unresponsive NMIBC, and the potential impact of combining cretostimogene with pembrolizumab on addressing unmet needs in NMIBC care.